The impact of center experience on results of reduced intensity: allogeneic hematopoietic SCT for AML. An analysis from the Acute Leukemia Working Party of the EBMT
暂无分享,去创建一个
G. Mufti | C. Craddock | M. Labopin | D. Blaise | A. Nagler | M. Mohty | D. Niederwieser | J. Janssen | F. Frassoni | J. Cornelissen | V. Rocha | A. Bacigalupo | N. Milpied | R. Arnold | L. Vindeløv | M. Saduś-Wojciechowska | S. Giebel | E. Petersen
[1] R. Brand,et al. Introduction of a quality management system and outcome after hematopoietic stem-cell transplantation. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] A. Ganser,et al. Association of Human Development Index with rates and outcomes of hematopoietic stem cell transplantation for patients with acute leukemia. , 2010, Blood.
[3] A. Gratwohl,et al. The EBMT activity survey 2007 with focus on allogeneic HSCT for AML and novel cellular therapies , 2009, Bone Marrow Transplantation.
[4] S. Forman. What is the role of reduced-intensity transplantation in the treatment of older patients with AML? , 2009, Hematology. American Society of Hematology. Education Program.
[5] R. Soiffer,et al. Variation in supportive care practices in hematopoietic cell transplantation. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[6] R. Soiffer,et al. Individual physician practice variation in hematopoietic cell transplantation. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] F. Appelbaum,et al. Hematopoietic-cell transplantation at 50. , 2007, The New England journal of medicine.
[8] D. Blaise,et al. Current status of reduced-intensity-conditioning allogeneic stem cell transplantation for acute myeloid leukemia. , 2007, Haematologica.
[9] N. Schmitz,et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe , 2002, Bone Marrow Transplantation.
[10] J. Esteve,et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) , 2005, Leukemia.
[11] D. Blaise,et al. The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison , 2005, Leukemia.
[12] J. Klein,et al. Association of transplant center and physician factors on mortality after hematopoietic stem cell transplantation in the United States. , 2005, Blood.
[13] J. Golmard,et al. Evaluation of centre and period effects in allogeneic haematopoietic stem cell transplantation in France , 2004, Bone Marrow Transplantation.
[14] A. Gratwohl,et al. Increasing use of reduced intensity conditioning transplants: report of the 2001 EBMT activity survey , 2002, Bone Marrow Transplantation.
[15] K. Matsuo,et al. Hospital capacity and post-transplant survival after allogeneic bone marrow transplantation: analysis of data from the Japan Society for Hematopoietic Cell Transplantation , 2000, Bone Marrow Transplantation.
[16] J. Sierra,et al. Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia , 2000, The Lancet.
[17] Robert Gray,et al. A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .
[18] J Crowley,et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.
[19] A. Nagler,et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. , 1998, Blood.
[20] E. Estey,et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. , 1997, Blood.
[21] A. Rimm,et al. Should HLA-identical sibling bone marrow transplants for leukemia be restricted to large centers? , 1992, Blood.